Holen Sie sich die Stockscreener-App
33.48
0.92%
0.25
Collegium Pharmaceutical Inc Aktie (COLL) Neueste Nachrichten
Collegium Pharmaceutical EVP Sells Nearly 50,000 Shares Worth $2 Million - Yahoo Finance
Collegium Pharmaceutical, Inc. (COLL) Discusses Acquisition of AZSTARYS to Expand ADHD Portfolio and Accelerate GrowthSlideshow (NASDAQ:COLL) 2026-03-24 - Seeking Alpha
Collegium Pharmaceutical Stock Gains Momentum After Key Debt Repayment and Strong Earnings Momentum - AD HOC NEWS
Collegium Pharmaceutical (COLL) Valuation Check After Recent Share Price Volatility - Sahm
Insider Selling: Collegium Pharmaceutical (NASDAQ:COLL) EVP Sells 13,976 Shares of Stock - MarketBeat
Dieter David, Collegium Pharmaceutical EVP, sells $488k in stock By Investing.com - Investing.com Canada
Collegium (NASDAQ: COLL) EVP trades 13,976 shares under 10b5-1 plan - Stock Titan
Collegium Pharmaceuticals: Another M&A Episode Adds To An Intriguing Case (NASDAQ:COLL) - Seeking Alpha
Collegium Pharmaceutical stock faces scrutiny amid opioid market shifts and regulatory pressures - AD HOC NEWS
Pharma M&A Roundup: Novartis to Acquire Pan-Mutant-Selective PI3Kα Inhibitor from Synnovation Therapeutics, Collegium to Acquire Azstarys from Corium Therapeutics - Pharmaceutical Executive
Azstarys (re-)born with Collegium’s ADHD buy - BioWorld MedTech
Collegium Pharmaceutical Expands ADHD Portfolio With AZSTARYS And Valuation Gap - simplywall.st
Needham & Company LLC Reiterates Buy Rating for Collegium Pharmaceutical (NASDAQ:COLL) - MarketBeat
Collegium Pharmaceutical (NASDAQ:COLL) Given Buy Rating at HC Wainwright - MarketBeat
Collegium to acquire Azstarys from Corium Therapeutics - The Pharma Letter
Collegium Pharmaceutical to Acquire AZSTARYS® for $650 Million, Expanding ADHD Portfolio and Projecting Over $50 Million Revenue in Late 2026 - Minichart
Collegium Pharmaceutical to acquire AZSTARYS for $650 million By Investing.com - Investing.com Australia
Jefferies reiterates Collegium Pharmaceutical stock Buy on ADHD deal By Investing.com - Investing.com Canada
Collegium Pharmaceutical to Acquire AZSTARYS ADHD Franchise - TipRanks
Collegium (NASDAQ: COLL) to acquire AZSTARYS in $650M ADHD expansion deal - Stock Titan
Barclays reiterates Collegium Pharmaceutical stock rating at Overweight By Investing.com - Investing.com Canada
Collegium Pharmaceutical (NASDAQ:COLL) Shares Gap UpShould You Buy? - MarketBeat
Collegium ponies up $650M to gain ADHD drug Azstarys from Corium - Fierce Pharma
Collegium Pharmaceutical to acquire Corium's ADHD drug for up to $785 million - marketscreener.com
Collegium Pharmaceutical to Buy AZSTARYS for $650M, Expanding ADHD Franchise Through 2037 - MarketBeat
Collegium Pharmaceutical to acquire AZSTARYS for $650 million - Investing.com
Collegium Pharmaceutical to Acquire Azstarys From Corium Therapeutics for $650 Million in Cash - marketscreener.com
Collegium to Acquire AZSTARYS® from Corium Therapeutics, - GlobeNewswire
Collegium to Acquire AZSTARYS® from Corium Therapeutics, Strengthening Position in ADHD and Accelerating Growth Trajectory - Sahm
Fidelity lists 13,976 COLL shares for sale (NASDAQ: COLL) - Stock Titan
Whale Trades: What are analysts price targets for Collegium Pharmaceutical Inc2026 EndofMonth & Expert Curated Trade Setup Alerts - baoquankhu1.vn
BrightSpring Health Services, Collegium Pharmaceutical, and Phibro Animal Health Shares Are Soaring, What You Need To Know - Yahoo Finance
Member Spotlight: Collegium Pharmaceutical - Massachusetts Biotechnology Council
Collegium Pharmaceutical, Inc. $COLL Position Reduced by Eventide Asset Management LLC - MarketBeat
Collegium Pharmaceutical touts record 2025, sees JORNAY PM driving 2026 growth at Barclays Miami Conference - MarketBeat
A Look At Collegium Pharmaceutical (COLL) Valuation After Recent Share Price Pressure - Yahoo Finance
3 Healthcare Stocks Walking a Fine Line - The Globe and Mail
Insider Sell: David Dieter Sells Shares of Collegium Pharmaceuti - GuruFocus
Risk Recap: What is the dividend yield of Collegium Pharmaceutical IncIndex Update & Weekly Setup with ROI Potential - baoquankhu1.vn
Collegium (NASDAQ: COLL) EVP sells 6,224 shares under 10b5-1 plan - Stock Titan
Collegium Pharmaceutical at Barclays Conference: Strategic Growth and Challenges By Investing.com - Investing.com Canada
WINTON GROUP Ltd Purchases Shares of 65,345 Collegium Pharmaceutical, Inc. $COLL - MarketBeat
Victory Capital Management Inc. Cuts Stock Position in Collegium Pharmaceutical, Inc. $COLL - MarketBeat
Collegium Pharmaceutical (COLL) Surged Following Record Quarterly Results - Insider Monkey
Jefferies Financial Group Inc. Takes $4.43 Million Position in Collegium Pharmaceutical, Inc. $COLL - MarketBeat
Assessing Collegium Pharmaceutical (COLL) Valuation After Recent Share Price Weakness - simplywall.st
[144] COLLEGIUM PHARMACEUTICAL, INC SEC Filing - Stock Titan
Market Catalysts: Can Collegium Pharmaceutical Inc be the next market leaderMarket Movers & Free Expert Verified Stock Movement Alerts - baoquankhu1.vn
Collegium Pharmaceutical, Inc. (COLL) gains momentum on Jornay PM, Truist highlights robust pain portfolio - MSN
Dow Update: Will Collegium Pharmaceutical Inc benefit from green energy policiesTrade Volume Report & Smart Money Movement Alerts - baoquankhu1.vn
(COLL) Volatility Zones as Tactical Triggers - Stock Traders Daily
Pharma News: Can Collegium Pharmaceutical Inc benefit from deglobalizationQuarterly Market Summary & Free Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
Collegium to Present New Real-World Data at PainConnect 2026 - Sahm
Citigroup Inc. Decreases Stock Holdings in Collegium Pharmaceutical, Inc. $COLL - MarketBeat
Insider Sell: Scott Dreyer Sells 49,976 Shares of Collegium Phar - GuruFocus
Scott Dreyer Sells 49,976 Shares of Collegium Pharmaceutical (NASDAQ:COLL) Stock - MarketBeat
3.61%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):